Thrombotic risk in the antiphospholipid syndrome

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 7, 2014, Pages 741-746

  Lim, Wendy ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

anti 2< inf> glycoprotein I antibodies; anticardiolipin antibodies; antiphospholipid antibodies; antiphospholipid syndrome; lupus anticoagulant

Indexed keywords

ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL THROMBOEMBOLISM; ARTERY THROMBOSIS; ARTICLE; HUMAN; MORBIDITY; PREGNANCY; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; BLOOD; COMPLICATION; FEMALE; PREGNANCY COMPLICATIONS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS; THROMBOSIS;

EID: 84928553348     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1390003     Document Type: Article

References (43)

1. Ruiz-Irastorza G., Cuadrado M. J., Ruiz-Arruza I., et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus: 2011; 20 2 206 218
2. Cervera R., Serrano R., Pons-Estel G. J., et al. on behalf of the Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis: 2014; (e-pub ahead of print). doi: 10.1136/annrheumdis-2013-204838.
3. Gris J. C., Bouvier S., Molinari N., et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood: 2012; 119 11 2624 2632
4. Wilson W. A., Gharavi A. E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum: 1999; 42 7 1309 1311
5. Miyakis S., Lockshin M. D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: 2006; 4 2 295 306
6. Pengo V., Tripodi A., Reber G., et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost: 2009; 7 10 1737 1740
7. Lockshin M. D., Sammaritano L. R., Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum: 2000; 43 2 440 443
8. Harris E. N., Pierangeli S. S. Primary, secondary, and catastrophic antiphospholipid syndrome: what's in a name? Semin Thromb Hemost: 2008; 34 3 219 226
9. Galli M., Luciani D., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood: 2003; 101 5 1827 1832
10. Galli M., Borrelli G., Jacobsen E. M., et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood: 2007; 110 4 1178 1183
11. Galli M., Luciani D., Bertolini G., Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood: 2003; 102 8 2717 2723
12. Tincani A., Filippini M., Scarsi M., Galli M., Meroni P. L. European attempts for the standardisation of the antiphospholipid antibodies. Lupus: 2009; 18 10 913 919
13. Favaloro E. J., Wheatland L., Jovanovich S., Roberts-Thomson P., Wong R. C. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I-Anticardiolipin and anti-β2-glycoprotein I antibodies. Semin Thromb Hemost: 2012; 38 4 390 403
14. Favaloro E. J., Bonar R., Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II-Lupus anticoagulant. Semin Thromb Hemost: 2012; 38 4 404 411
15. Kershaw G., Suresh S., Orellana D., Nguy Y. M. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost: 2012; 38 4 375 384
16. Pengo V., Ruffatti A., Legnani C., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost: 2010; 8 2 237 242
17. Urbanus R. T., Siegerink B., Roest M., Rosendaal F. R., de Groot P. G., Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol: 2009; 8 11 998 1005
18. Pengo V., Biasiolo A., Pegoraro C., Cucchini U., Noventa F., Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost: 2005; 93 6 1147 1152
19. Ruffatti A., Olivieri S., Tonello M., et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost: 2008; 6 10 1693 1696
20. Brey R. L., Abbott R. D., Curb J. D., et al. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program. Stroke: 2001; 32 8 1701 1706
21. de Groot P. G., Lutters B., Derksen R. H., Lisman T., Meijers J. C., Rosendaal F. R. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost: 2005; 3 9 1993 1997
22. Ruffatti A., Tonello M., Del Ross T., et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost: 2006; 96 3 337 341
23. Forastiero R., Martinuzzo M., Pombo G., et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost: 2005; 3 6 1231 1238
24. McNeil H. P., Simpson R. J., Chesterman C. N., Krilis S. A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A: 1990; 87 11 4120 4124
25. Galli M., Comfurius P., Maassen C., et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet: 1990; 335 8705 1544 1547
26. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet: 1990; 336 8708 177 178
27. Sène D., Piette J. C., Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev: 2008; 7 4 272 277
28. Oosting J. D., Derksen R. H., Entjes H. T., Bouma B. N., de Groot P. G. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost: 1992; 67 5 499 502
29. Roubey R. A., Pratt C. W., Buyon J. P., Winfield J. B. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest: 1992; 90 3 1100 1104
30. de Laat B., Derksen R. H., Urbanus R. T., de Groot P. G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood: 2005; 105 4 1540 1545
31. Bevers E. M., Galli M., Barbui T., Comfurius P., Zwaal R. F. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost: 1991; 66 6 629 632
32. Iverson G. M., Victoria E. J., Marquis D. M. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A: 1998; 95 26 15542 15546
33. de Laat B., Derksen R. H., van Lummel M., Pennings M. T., de Groot P. G. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood: 2006; 107 5 1916 1924
34. Ioannou Y., Pericleous C., Giles I., Latchman D. S., Isenberg D. A., Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum: 2007; 56 1 280 290
35. Tektonidou M. G., Laskari K., Panagiotakos D. B., Moutsopoulos H. M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum: 2009; 61 1 29 36
36. Cervera R., Khamashta M. A., Shoenfeld Y., et al. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis: 2009; 68 9 1428 1432
37. Ruiz-Irastorza G., Hunt B. J., Khamashta M. A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum: 2007; 57 8 1487 1495
38. Ruiz-Irastorza G., Khamashta M. A., Hunt B. J., Escudero A., Cuadrado M. J., Hughes G. R. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med: 2002; 162 10 1164 1169
39. Crowther M. A., Ginsberg J. S., Julian J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med: 2003; 349 12 1133 1138
40. Finazzi G., Marchioli R., Brancaccio V., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost: 2005; 3 5 848 853
41. Schulman S., Svenungsson E., Granqvist S.; Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med: 1998; 104 4 332 338
42. Levine S. R., Brey R. L., Tilley B. C., et al. APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA: 2004; 291 5 576 584
43. Okuma H., Kitagawa Y., Yasuda T., Tokuoka K., Takagi S. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci: 2009; 7 1 15 18